Well-publicised public comments by European leaders strongly suggesting that the Anglo-Swedish AstraZeneca vaccine was less effective for older age groups have translated into many doses going unused. While Germany and France lag behind in the race to immunise their populations, barely hitting six percent while the UK is close to 26 percent, much of the blame for this situation lies at the door of President Macron of France and several leading German politicians who claimed that the much cheaper and easier to handle AstraZeneca vaccine was unsuitable for anyone over the age of 65, and as Macron implied, possibly for anyone over 60. Since those accusations circulated, two things have happened. Reputable agencies including the World Health Organisation and the European Medicines Agency have said that based on clinical evidence AstraZeneca works well in all age groups. The second development is that large swaths of the European public have refused to take it. Reports from Germany are rather alarming.